Safety of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease-Reference-Cited by-同舟云学术

Safety of Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease

Published:2022-02-24 Issue:10 Volume:63 Page:1503-1508
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Alsadik Shahad,Gnanasegaran Gopinath,Chen Luohai,Mandair Dalvinder,Toumpanakis Christos,Caplin Martyn,Navalkissoor Shaunak

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference28 articles.

1. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

2. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

3. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

4. Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

5. Annex I: summary of product characteristics. EMA website. https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf. Accessed July 7, 2022.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimation of kidney doses from [177Lu]Lu-DOTA-TATE PRRT using single time point post-treatment SPECT/CT;EJNMMI Physics;2024-07-25

2. 177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors;Clinical Nuclear Medicine;2024-06-20

3. Use of approved Lu‐177 radiopharmaceuticals in patients with end‐stage renal disease: A review of the literature and proposed treatment algorithm;Journal of Neuroendocrinology;2024-04-15

4. Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update;Current Oncology Reports;2024-04-06

5. Cancer theranostics: recent global advances;Functionalized Nanomaterials for Cancer Research;2024